OpenLB
Open Library of Bioscience
Advanced Search
Journal of virus eradication
Dec, 2023;9 (4): 100354.

Patient acceptability of, and attitudes towards, hepatitis B cure research - A scoping review and identification of knowledge gaps.

Neaka Mohtashemi, Karine Dub��, Chloe Thio, Sihyeong Song, Shail Patel, Jeremy Sugarman, Debika Bhattacharya
Author Information
  1. Neaka Mohtashemi: University of California, Los Angeles, Los Angeles, CA, USA.
  2. Karine Dub��: University of California, San Diego, San Diego, CA, USA.
  3. Chloe Thio: Johns Hopkins University, Baltimore, MD, USA.
  4. Sihyeong Song: University of California, Los Angeles, Los Angeles, CA, USA.
  5. Shail Patel: University of California, Los Angeles, Los Angeles, CA, USA.
  6. Jeremy Sugarman: Johns Hopkins University, Baltimore, MD, USA.
  7. Debika Bhattacharya: University of California, Los Angeles, Los Angeles, CA, USA.
PMID: 38161322 DOI: 10.1016/j.jve.2023.100354

Abstract

Functional cure, defined as durable loss of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA suppression off therapy, is an increasingly important goal in the treatment of chronic hepatitis B. Although novel treatments aimed at achieving functional cure are being developed and tested in clinical trials, it is important to assess the perspectives of people living with HBV towards these potential treatments and their participation in HBV functional cure research. We have performed a scoping review that revealed that there is limited knowledge regarding patient perspectives of HBV functional cure research and then identified gaps in knowledge for further investigation. Our work highlights the need for further studies in patient perspectives in HBV functional cure research.

Keywords

Clinical trials Functional cure HBV

References

  1. AIDS Res Hum Retroviruses. 2020 Apr;36(4):260-267 [PMID: 31608648]
  2. J Virus Erad. 2015 Oct;1:250-256 [PMID: 26866059]
  3. AIDS Res Hum Retroviruses. 2019 Jul;35(7):649-659 [PMID: 30990052]
  4. AIDS Res Hum Retroviruses. 2019 Jan;35(1):100-107 [PMID: 30009625]
  5. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1641-1649.e6 [PMID: 29505905]
  6. FEMS Immunol Med Microbiol. 2003 Oct 24;39(1):69-72 [PMID: 14556998]
  7. J Hepatol. 2022 Jun;76(6):1249-1262 [PMID: 35589248]
  8. Patient Prefer Adherence. 2020 Mar 19;14:613-624 [PMID: 32256052]
  9. J Clin Epidemiol. 2012 Jun;65(6):581-3 [PMID: 22537467]
  10. Hepatology. 2022 Jul;76(1):233-250 [PMID: 34990029]
  11. J Hepatol. 2020 Mar;72(3):539-557 [PMID: 31730789]
  12. Curr Treat Options Gastroenterol. 2019 Jun;17(2):271-291 [PMID: 31077059]
  13. J Virus Erad. 2020 Aug 25;6(4):100008 [PMID: 33294210]
  14. Patient. 2017 Jun;10(3):335-344 [PMID: 27882509]
  15. Curr Opin Virol. 2016 Jun;18:135-43 [PMID: 27447092]
  16. Nurs Open. 2017 Oct 23;4(4):310-318 [PMID: 29085657]
  17. Viruses. 2021 Dec 21;14(1): [PMID: 35062208]
  18. Virulence. 2022 Dec;13(1):1111-1132 [PMID: 35763282]
  19. Liver Int. 2011 Jan;31 Suppl 1:78-84 [PMID: 21205142]
  20. Am J Public Health. 2005 Jul;95(7):1123-7 [PMID: 15983268]
  21. Viruses. 2022 Oct 29;14(11): [PMID: 36366502]
  22. Harm Reduct J. 2018 Aug 15;15(1):42 [PMID: 30111327]
  23. BMC Public Health. 2021 May 28;21(1):1004 [PMID: 34044808]
  24. PLoS One. 2020 Mar 4;15(3):e0229733 [PMID: 32130262]
  25. Gut. 2015 Dec;64(12):1972-84 [PMID: 26048673]
  26. Gut. 2018 Apr;67(4):767-775 [PMID: 29331944]
  27. Antivir Ther. 2013;18(5):663-70 [PMID: 23232291]
  28. J Viral Hepat. 2021 Nov;28(11):1539-1544 [PMID: 34363715]
  29. Arch Phys Med Rehabil. 2022 Aug;103(8):1684-1692 [PMID: 35307343]
  30. J Gen Intern Med. 2014 Mar;29(3):477-84 [PMID: 24352635]
  31. Viruses. 2020 May 07;12(5): [PMID: 32392763]
  32. Clin Infect Dis. 2022 Aug 24;75(1):3-10 [PMID: 34699587]
  33. Adv Ther. 2019 Sep;36(9):2475-2486 [PMID: 31240629]
  34. J Hepatol. 2017 Oct;67(4):847-861 [PMID: 28778687]
  35. Virus Res. 2018 Jan 15;244:304-310 [PMID: 28627393]
  36. Hepatol Commun. 2022 May;6(5):935-949 [PMID: 34894108]
  37. J Hepatol. 2017 Aug;67(2):370-398 [PMID: 28427875]
  38. Health Expect. 2016 Jun;19(3):691-701 [PMID: 24112277]
  39. J Virus Erad. 2022 Feb 25;8(1):100066 [PMID: 35280938]
  40. BMJ Open. 2022 Mar 9;12(3):e055642 [PMID: 35264360]
  41. Dig Dis Sci. 2021 Feb;66(2):434-441 [PMID: 32239377]
  42. Curr Opin Virol. 2016 Jun;18:109-16 [PMID: 27318098]
  43. Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):238-253 [PMID: 36631717]

Grants

  1. R25 MH067127/NIMH NIH HHS
Journal Article Scoping Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0cureHBVhepatitisBfunctionalresearchperspectivesknowledgeFunctionalimportanttreatmentstrialstowardsscopingreviewpatientgapsdefineddurablelosssurfaceantigenHBsAgvirusDNAsuppressiontherapyincreasinglygoaltreatmentchronicAlthoughnovelaimedachievingdevelopedtestedclinicalassesspeoplelivingpotentialparticipationperformedrevealedlimitedregardingidentifiedinvestigationworkhighlightsneedstudiesPatientacceptabilityattitudes-identificationClinical

Similar Articles

Cited By (1)